Optellum, a medtech company that provides a ground-breaking AI platform to diagnose and treat early-stage lung cancer, is attending this year’s American Thoracic Society International Conference in conjunction with three prominent American healthcare institutions. Physicians from each of these institutions will demonstrate how integrating Optellum Virtual Nodule Clinic into their clinical workflows offers benefits for both patients and providers.
Attendees at the conference can learn more about the application of the Optellum Virtual Nodule Clinic at these three scheduled sessions:
- May 22, 4:15pm — Oral presentation by Dr. Caroline Godfrey, General Surgery Resident at Vanderbilt University Medical Center, “The Use of Rapid On-site Evaluation During Navigational Bronchoscopy for Peripheral Pulmonary Lesions: A Cost Effectiveness Model”
- May 24, 8am — Poster discussion session with Dr. Christina Bellinger and Dr. Travis L. Dotson of Atrium Health Wake Forest Baptist Medical Center, “Identifying Patients with Pulmonary Nodules from CT Radiology Reports Using Natural-Language Processing (NLP)”
- May 24, 8am — Poster discussion session with Dr. Roger Kim and Dr. Anil Vachani of Penn Medicine, “Theoretical Net Benefit of a Radiomics-Based Computer-Aided Diagnosis Tool for Risk Stratification of Pulmonary Nodules”
The work at Vanderbilt Health demonstrates the cost-effectiveness of the AI platform, which was assigned CPT code 0721T in 2022 to facilitate health insurance claims for patients. At Atrium Health Wake Forest Baptist, Dr. Bellinger and her colleagues have been using the innovative system along with robotic bronchoscopy to help better prediction and diagnosis of lung cancer. Dr. Anil Vachani was the lead investigator for Optellum’s FDA clearance, the first of its kind achieved in 2021, and his work with Dr. Kim showing that clinical decision making is better if the AI tool is incorporated into radiology or pulmonology practice was published in Radiology in 2022.
Optellum Virtual Nodule Clinic is in use at other leading hospitals in the US and being rolled-out in a government-funded widespread screening trial in the UK’s National Health System (NHS). The company was named as one of the 150 most promising digital health companies of 2022 by CB Insights.
